DYN
Dyne Therapeutics, Inc. · Healthcare · Market cap $3.0B
Insiders sold $72.3M net in the last 90 days ·6 sellers, 1 buyer· 12 of 12 sales under Rule 10b5-1 plans· latest Form 4 filed Oct 6, 2026
Insider Buying
$315K
reported purchases (SEC code P)
Insider Selling
$168.6M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Latest filing
Oct 22, 2026
Posner Brian S
Dyne Therapeutics, Inc. (DYN) has 52 SEC Form 4 filings (136 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Oct 22, 2026.
Inside the rolling window, 7 insiders at Dyne Therapeutics, Inc. reported 8 open-market purchases totaling $315K and 57 open-market sales totaling $168.6M. The most active filer is Director Rhodes Jason P with 19 filings. Insiders have net sold $127.0M over the trailing 6 months. The most recent open-market filing is a purchase of 2,500 shares by Director Posner Brian S, dated Oct 2, 2026, worth $40K.
- Industry:Biotechnology
- CEO:John G. Cox
- Employees:289
- HQ:Waltham, MA, US
- IPO:2020-09-17
| Source | |||||||
|---|---|---|---|---|---|---|---|
Posner Brian SFirst in 4 months | Director | Purchase | 2,500 | $40K | Oct 6 | +4.4% | SEC ↗ |
| Chief Medical Officer | Sale | 3,745 | $91K | Sep 8 | -20.9% | SEC ↗ | |
| Chief Medical Officer | Sale | 1,290 | $24K | Sep 8 | -20.9% | SEC ↗ | |
| Chief Commercial Officer | Sale | 900 | $22K | Sep 8 | -20.9% | SEC ↗ | |
| Chief Commercial Officer | Sale | 185 | $3K | Sep 8 | -20.9% | SEC ↗ | |
| CEO & President | Sale | 5,658 | $107K | Sep 8 | -20.9% | SEC ↗ | |
| Chief Financial Officer | Sale | 1,797 | $47K | Aug 17 | -38.5% | SEC ↗ | |
| CEO & President | Sale | 4,986 | $131K | Aug 17 | -38.5% | SEC ↗ | |
| Chief Medical Officer | Sale | 1,556 | $41K | Aug 17 | -38.5% | SEC ↗ | |
| Director | Sale | 426,412 | $11.2M | Aug 17 | -38.5% | SEC ↗ | |
| Director | Sale | 2,160,516 | $54.0M | Aug 17 | — | SEC ↗ | |
| Chief Commercial Officer | Sale | 226 | $6K | Aug 17 | — | SEC ↗ | |
| Director | Sale | 261,460 | $6.7M | Jul 29 | — | SEC ↗ | |
| Director | Sale | 480,240 | $10.9M | Jul 8 | — | SEC ↗ | |
| Director | Sale | 297,211 | $6.9M | Jul 8 | — | SEC ↗ | |
| Director | Sale | 309,268 | $6.6M | Jun 30 | — | SEC ↗ | |
| Director | Sale | 195,427 | $4.1M | Jun 30 | — | SEC ↗ | |
| Director | Sale | 147,760 | $3.1M | Jun 26 | — | SEC ↗ | |
| Director | Sale | 95,900 | $2.0M | Jun 26 | — | SEC ↗ | |
| Director | Sale | 24,100 | $509K | Jun 26 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 2,362 | $48K | Jun 26 | — | SEC ↗ | |
| Director | Sale | 190,676 | $3.9M | Jun 24 | — | SEC ↗ | |
| Director | Sale | 73,286 | $1.5M | Jun 24 | — | SEC ↗ | |
| Director | Sale | 37,454 | $754K | Jun 22 | — | SEC ↗ | |
| Director | Sale | 46,901 | $941K | Jun 22 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does DYN have?
Dyne Therapeutics, Inc. (DYN) has 52 SEC Form 4 filings (136 transaction rows) in the rolling 365-day window, disclosed by 7 distinct insiders. Most recent filing: Oct 22, 2026.
When was the most recent SEC Form 4 filing for DYN?
The most recent Form 4 filing for DYN on Tracefour is dated Oct 22, 2026.
Who is the most active insider at DYN?
The most active SEC Form 4 filer at DYN in the rolling window is Director Rhodes Jason P, with 19 filings.
What is the net insider flow at DYN over the last 6 months?
Over the trailing 180 days, insiders at DYN have net sold $127.0M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at DYN in the current window?
Inside the rolling window, insiders at DYN bought $315K and sold $168.6M based on SEC Form 4 filings.
Can I get alerts for DYN insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Dyne Therapeutics, Inc. (DYN). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Dyne Therapeutics, Inc. is in the Healthcare sector.